Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

French (CAC) Pharma Industry Analysis

UpdatedSep 29, 2025
DataAggregated Company Financials
Companies6
  • 7D-2.4%
  • 3M-4.4%
  • 1Y-22.0%
  • YTD-15.3%

Over the last 7 days, the Pharma industry has dropped 2.4%, driven by a pullback from Sanofi of 2.4%. Overall the industry is down 22% in 12 months. Looking forward, earnings are forecast to grow by 11% annually.

Industry Valuation and Performance

Has the French Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 30 Sep 2025€108.8b€52.8b€6.9b19.7x15.7x2.1x
Thu, 28 Aug 2025€119.5b€52.8b€6.9b19.5x17.3x2.3x
Sat, 26 Jul 2025€117.5b€52.1b€6.7b20.9x17.7x2.3x
Mon, 23 Jun 2025€113.9b€52.1b€6.7b18.6x17.1x2.2x
Wed, 21 May 2025€126.7b€52.1b€6.7b18.3x19x2.4x
Fri, 18 Apr 2025€122.6b€51.2b€5.9b17.8x20.6x2.4x
Sun, 16 Mar 2025€146.2b€51.2b€5.9b18x24.6x2.9x
Tue, 11 Feb 2025€143.8b€51.1b€6.3b18.5x22.9x2.8x
Thu, 09 Jan 2025€133.4b€55.2b€5.1b19.3x26.2x2.4x
Sat, 07 Dec 2024€129.0b€55.2b€5.1b19.5x25.3x2.3x
Mon, 04 Nov 2024€137.8b€55.2b€5.1b20.8x27.1x2.5x
Wed, 02 Oct 2024€144.5b€53.8b€4.8b22.4x30.1x2.7x
Fri, 30 Aug 2024€141.0b€53.8b€4.8b19.8x29.4x2.6x
Sun, 28 Jul 2024€134.6b€53.8b€4.9b21.6x27.5x2.5x
Tue, 25 Jun 2024€127.5b€52.9b€5.2b20.5x24.7x2.4x
Thu, 23 May 2024€128.8b€52.9b€5.2b22.3x24.9x2.4x
Sat, 20 Apr 2024€120.3b€52.7b€6.0b19.7x19.9x2.3x
Mon, 18 Mar 2024€123.7b€52.6b€6.0b20.4x20.5x2.4x
Wed, 14 Feb 2024€121.3b€53.0b€6.3b19.6x19.3x2.3x
Fri, 12 Jan 2024€133.2b€52.2b€9.7b19.3x13.7x2.6x
Sun, 10 Dec 2023€121.2b€52.2b€9.7b16.8x12.5x2.3x
Tue, 07 Nov 2023€120.2b€52.2b€9.7b16.4x12.4x2.3x
Thu, 05 Oct 2023€143.1b€52.6b€9.3b18.7x15.4x2.7x
Sat, 02 Sep 2023€138.8b€52.6b€9.3b20.9x15x2.6x
Mon, 31 Jul 2023€133.9b€52.6b€9.2b20.2x14.5x2.5x
Wed, 28 Jun 2023€136.2b€52.6b€9.1b14.8x14.9x2.6x
Fri, 26 May 2023€140.4b€52.6b€9.1b15.6x15.4x2.7x
Sun, 23 Apr 2023€142.5b€51.8b€9.2b15.3x15.6x2.8x
Tue, 21 Mar 2023€125.4b€51.7b€9.2b14.6x13.7x2.4x
Thu, 16 Feb 2023€124.3b€51.7b€7.5b18.4x16.5x2.4x
Sat, 14 Jan 2023€128.3b€50.7b€7.4b17.9x17.4x2.5x
Mon, 12 Dec 2022€125.0b€50.7b€7.4b17.5x17x2.5x
Wed, 09 Nov 2022€122.6b€50.7b€7.4b17.1x16.7x2.4x
Fri, 07 Oct 2022€113.5b€48.4b€7.6b17.8x15x2.3x
Price to Earnings Ratio

15x


Total Market Cap: €113.5bTotal Earnings: €7.6bTotal Revenue: €48.4bTotal Market Cap vs Earnings and Revenue0%0%0%
French Pharma Industry Price to Earnings3Y Average 19.4x202320242025
Current Industry PE
  • Investors are pessimistic on the French Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 15.7x which is lower than its 3-year average PE of 19.4x.
  • The 3-year average PS ratio of 2.5x is higher than the industry's current PS ratio of 2.1x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have declined 3.1% per year over the last three years.
  • Meanwhile revenues for these companies have grown 3.0% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the French Healthcare industry?

FR Market0.44%
Healthcare-2.01%
Pharma-2.42%
Pharma-2.42%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
MEDCL MedinCell€23.208.4%
+€59.6m		48.0%PS27.7x
ALDVI Advicenne€1.5017.3%
+€3.1m		61.5%PS3.6x

Latest News

SAN
€78.28
Sanofi
7D
-2.4%
1Y
-23.9%
ALDVI
€1.50
Advicenne
7D
17.3%
1Y
61.5%
MEDCL
€23.20
MedinCell
7D
8.4%
1Y
48.0%

Global Expansion And Extended Patents Will Unlock Future Opportunities

The upward revision in MedinCell's price target reflects a significant increase in consensus revenue growth forecasts coupled with a notable decline in the future P/E ratio, resulting in a new fair value estimate of €24.47. What's in the News UZEDY, a long-acting injectable risperidone for schizophrenia, received regulatory approval in South Korea and will be distributed by Teva Handok.
IPN
€113.40
Ipsen
7D
-2.2%
1Y
2.6%

Pipeline Catalysts And Approvals Will Expand Global Access

Driven by a modest uptick in consensus revenue growth forecasts and a slight increase in the projected future P/E, Ipsen’s analyst price target has inched up from €127.00 to €128.43. What's in the News Ipsen received Japanese regulatory approval for Bylvay (odevixibat) for the treatment of pruritus associated with progressive familial intrahepatic cholestasis (PFIC), with commercialization managed by Ipsen in Japan.
VETO
€76.50
Vetoquinol
7D
-1.0%
1Y
-8.5%
VIRP
€314.00
Virbac
7D
-0.3%
1Y
-18.0%

Analysts Have Made A Financial Statement On Virbac SA's (EPA:VIRP) First-Quarter Report

Sep 17
Analysts Have Made A Financial Statement On Virbac SA's (EPA:VIRP) First-Quarter Report
AB
€1.24
AB Science
7D
-4.6%
1Y
24.5%
EAPI
€3.01
Euroapi
7D
-4.0%
1Y
-20.6%

Euroapi S.A. (EPA:EAPI) Just Released Its Interim Results And Analysts Are Updating Their Estimates

Aug 02
Euroapi S.A. (EPA:EAPI) Just Released Its Interim Results And Analysts Are Updating Their Estimates
ALTHX
€2.32
Theranexus Société Anonyme
7D
-2.5%
1Y
346.2%
MLCOT
€0.13
Coretech 5 Société anonyme
7D
-4.4%
1Y
738.7%